An Open-Label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL Tablets (Risperidone) to an Equivalent Dose of a Rapidly-Dissolving Tablet Formulation of Risperidone.
Phase of Trial: Phase III
Latest Information Update: 04 May 2010
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen Inc
- 14 Apr 2009 Planned number of patients changed from 100 to 82 as reported by ClinicalTrials.gov.
- 19 Oct 2007 Status changed from in progress to completed.
- 08 Aug 2006 Status change